About the Event
New results from trials in 3 countries prove that Immunicom’s LW-02 delivered via their breakthrough Immunopheresis® Molecular Platform reduces brain metastasis by 75%! This is a huge development for a prominent condition for late stage cancer patients.
- Has received FDA Breakthrough Designation
- Turns immune resistant “cold” tumors into immune activated “hot” tumors
- Has minimal toxicity and side effects
- Has Patent Protection to 2039/2040 and beyond
Join our webinar with Immunicom CEO, Amir Jafri to hear more about the latest results, their platform’s streamlined regulatory path, and its blockbuster potential for treatment of Immuno-Oncology (IO), Cardiology, Respiratory, Auto-Immune, Renal, and Inflammatory diseases.